Cognate BioServices, a Memphis, Tenn.-based contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products, closed a Series B funding round of undisclosed amount and completed the acquisition of Cobra Biologics, a UK- and Sweden-based CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector.